As per reports, in accordance with its upcoming phase of expansion, John Hoke, a seasoned veteran with 30 years of experience at NIKE, Inc. (NKE), is poised to assume the position of Chief Innovation Officer at the company. Hoke, previously serving as Nike’s inaugural Chief Design Officer, will collaborate with Tom Clarke, President, Innovation, NIKE, Inc., to enhance and expedite Nike’s innovation strategy.
Assuming the position of Chief Design Officer, NIKE, Inc., will be Martin Lotti, a 26-year veteran of Nike. With extensive experience and leadership at Nike, Lotti steps into the top design role after recently serving as Chief Design Officer for the Jordan Brand. In his new capacity, Lotti will oversee all facets of Nike design, encompassing footwear, apparel, brand, and retail concepts.
These leadership transitions with Hoke and Lotti are effective immediately.
Nicole Hubbard Graham, an esteemed figure in the industry, is set to take on the role of Chief Marketing Officer at NIKE, Inc., effective January 2, 2024. With an impressive 18-year tenure at Nike, Graham, a former co-founder of Adopt, a minority-owned company and creative agency, will lead Nike’s Global Brand Marketing team. In her new position, she will oversee all aspects of Marketing, aligning the company’s brand voice with its upcoming phase of growth. Graham has previously held various global marketing leadership roles at Nike, showcasing her extensive experience across business and geographies.
She succeeds Dirk-Jan “DJ” van Hameren, a former Olympian and visionary leader, who has decided to retire next summer after an impactful 31-year journey with Nike. Van Hameren played a pivotal role in Nike’s global brand storytelling, leading the way for over three decades and contributing significantly to the development of the brand’s world-class Marketing team.
Dr. Muge Erdirik Dogan is appointed as Chief Technology Officer (CTO) at NIKE, Inc., where she will contribute significantly to advancing technological innovation for the company’s ambitious growth plans. Joining the executive leadership team, Dr. Dogan will report directly to John Donahoe, President & CEO, NIKE, Inc. Her commencement in the new role at Nike is slated for November 27, 2023.
NIKE, Inc. (NKE) is the world’s top designer, marketer, and distributor of athletic footwear, equipment, apparel, and accessories. The Beaverton, Oregon-based company offers products for a wide variety of sports and fitness activities. To learn more about NIKE, Inc. (NIKE) and to continue to track its progress please visit the Vista Partners NIKE Coverage Page.
DID YOU KNOW?…
An Unmet Need in Diabetes Care
- While Insulin Pumps Improve Glycemic Control,1-4 2 in 3 People with Type 1 Diabetes Still Manually Inject Insulin…
- Tens of thousands of people suffer annually from the complications of diabetes, such as cardiovascular events, neuropathy, dementia, kidney disease, blindness and lower limb amputation – frequent consequences of poorly managed glycemic control.
- There are 1.9 million individuals with Type 1 Diabetes in the US. 100% of patient population require daily insulin injection. Only 1 out of 3 currently use an insulin pump.
- 32% of population utilizes insulin pumps for diabetes management
- 68% of the population rely on multiple daily injections for diabetes management.
- Almost Pumpers are 30% of the market. They would choose an insulin pump if it were less expensive, took less time to learn and use, and posed a low technological hurdle. This is believed to be a $1.9B market opportunity.
On Oct. 31, Modular Medical provided an update on its ongoing pre-submission testing and timeline for submission of its MODD-1 insulin pump (the “MODD-1”) to the U.S. Food and Drug Administration (“FDA”). The Company has made substantial progress on completing many of the tests required for submission and now has results back from some of the longest lead time tests, including insulin stability and potency. Modular Medical believes the test results received from multiple third-party laboratory tests are sufficient for submission of the MODD1 to the FDA for clearance, subject to the completion of other ongoing tests and reports. Jeb Besser, CEO of Modular Medical, commented, “The Modular Medical team has continued to make rapid progress towards our 510(k) submission to the FDA, since the completion of our pilot manufacturing line in August. While there is still additional testing to be done, we are starting to gain better visibility on our submission timeline, and we currently expect to make our FDA submission around year end 2023. We remain excited about our opportunity to bring access to better insulin delivery to underserved segments of the market.”